Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT 201 (Xeomin) in pediatric lower limb spasticity due to cerebral palsy
2023-503420-19-00Phase 3Completed
- Sponsor
- Merz
- Start
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in lower extremity spasticity and cerebral palsy (CP) comparing Xeomin (NT 201) with Placebo to NT 201 (2 arms). Primary endpoint: Change in derived modified Ashworth Scale (MAS) score of plantar flexors from baseline at week 4 and week 6. Started Oct 2022; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
lower extremity spasticitycerebral palsy (CP)
Beyond the preview
Go deeper on 2023-503420-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503420-19-00.